08:51 AM EDT, 03/27/2025 (MT Newswires) -- Spectral Medical ( EDTXF ) on Thursday said it swung to a fourth-quarter loss even as revenue advanced.

The company reported a loss from continuing operations of $3.2 million, compared with a profit of $6.5 million in the prior year period. Revenue increased to $645,000 from $365,000.

Spectral said enrollment in its ongoing Tigris trial has been strong, with 14 patients enrolled in 2025 year-to-date. The company is closing in on the full enrollment of 150 evaluable patients, possibly in the next few weeks.

In anticipation of a positive Tigris trial outcome, Spectral has been working on post-approval marketing plans for PMX commercialization, for the treatment of patients with septic shock.

"We are on the cusp of full Tigris enrollment, which marks a major clinical milestone for Spectral. Completion of the Tigris study represents a big step forward in the potential of bringing the PMX therapy to market, and we look forward to our continued partnership with Vantive, and the development of a robust commercialization strategy," said Chief Executive Officer Chris Seto. "Spectral is now entering a heavily-focused regulatory phase for PMX. The company will be providing a more comprehensive view on Spectral's regulatory pathway in the coming weeks."